To ask the Secretary of State for Health how many meetings officials have had with strategic health authority chief executives on the service level agreement applied to the provision of Recombinant Factor VIII to haemophiliacs; and whether the service level agreement has been finalised.
This funding was made available following a long campaign by the haemophilia lobby groups. Funding was available from the programme budget.
The roll-out programme for recombinant began in January 2004, and all haemophilia patients in England are now eligible for treatment with recombinant products.
Funding is now allocated to strategic health authorities through the national health service bundle, and will be managed through a service level agreement.